Showing 6061-6070 of 9451 results for "".
All in One
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/all-in-one/18726/The Sciton Joule platform offers multiple treatment options to address multiple indications in a single, scalable system, making it a top laser platform pick for 2017, says Dr. Cohen during Cosmetic Surgery Forum.Pico Pick-up: Expanding Applications
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/pico-pick-up-expanding-applications/18555/What started as a revolutionary approach to removing tattoos, is finding new applications for facial rejuvenation. The expanding use of picosecond technology is making the investment more attractive for aesthetically-focused practices, notes Dr. Gold.Differin Goes OTC, ISDIN Comes to America, Understand AD
https://practicaldermatology.com/topics/psoriasis/dermwiretv-differin-goes-otc-isdin-comes-to-america-understand-ad/18762/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. Regeneron Pharmaceuticals, Sanofi Genzyme, the National Eczema Association, and the Dermatology Nurses Association launch UnderBiosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentVanquish Approved for Circumferential Fat Reduction; Acquisition News
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-vanquish-approved-for-circumferential-fat-reduction-acquisition-news/18884/BTL's Vanquish Cleared for Circumferential Fat Reduction of the Abdomen, Filler Injections Gain Popularity Off the Face, Protein Linked to Aggressive Melanomas, and new acquisitions at Kythera, Lumenis, XTRAC.ASDS BCC Recommendations; Bad Online Reviews for Derms
https://practicaldermatology.com/topics/practice-management/dermwiretv-asds-bcc-recommendations-bad-online-reviews-for-derms/18906/This edition of DermWireTV, from the editors of Practical Dermatology® magazine reviews the new ASDS Consensus Recommendation for the management of Basal Cell Carcinoma (BCC). An expert panel found Mohs micrographic surgery is highly cost effective. In other news, researchers find that dermatologistKythera's Kybella Approved; ASLMS Update
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-kythera-s-kybella-approved-aslms-update/18925/FDA Approves Kythera's Kybella (ATX-101 or deoxycholic acid) injection for reduction of sub mental fullness or double chin. ASLMS Recognizes women in device-based medicine (Women in Energy-based Devices). Deka and Syneron get new clearances. ASDS Launches Skin Cancer PSAs, and Foamix sells shares.Valeant Acquires Salix; Actavis Changing Name
https://practicaldermatology.com/videos/dermwire-tv/valeant-acquires-salix-actavis-changing-name/18963/Valeant expands its portfolio with the acquisition of GI market leader Salix. Actavis divests Doryx and considers a name change to Allergan. Kythera acquires rights for investigational hair therapies. And Cynosure's 532nm laser delivery system is FDA cleared for PicoSure.Ask an Expert: Sheila Fallon Friedlander, MD on the Molluscum Pipeline
https://practicaldermatology.com/topics/general-topics/ask-an-expert-sheila-fallon-friedlander-md-on-the-molluscum-pipeline/19006/Sheila Fallon Friedlander, MD talks to host Adam Friedman, MD about the pipeline of treatments for molluscum in pediatric patients. From NewDermMD.Allergan Strikes $66 Billion Deal with Actavis
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-allergan-strikes-66-billion-deal-with-actavis/19021/In this edition of DermWireTV, host Ranna Jaraha discusses this week's blockbuster merger deal between Allergan and Actavis. Also featured in this edition is a new report detailing the rising costs of treating skin cancer, and high recognition for a dermatologic device manufacturer.